发明申请
US20120009172A1 INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR
审中-公开
直接作用和可逆的P2Y12抑制剂的口服和口服剂量
- 专利标题： INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR
- 专利标题（中）： 直接作用和可逆的P2Y12抑制剂的口服和口服剂量
-
申请号： US13235305申请日： 2011-09-16
-
公开(公告)号： US20120009172A1公开(公告)日： 2012-01-12
- 发明人: Daniel D. Gretler , Pamela B. Conley , Patrick Andre , Athiwat Hutchaleelaha , David R. Phillips , Anjali Pandey , Robert M. Scarborough , Carroll Anna Crew Scarborough , Wolin Huang
- 申请人： Daniel D. Gretler , Pamela B. Conley , Patrick Andre , Athiwat Hutchaleelaha , David R. Phillips , Anjali Pandey , Robert M. Scarborough , Carroll Anna Crew Scarborough , Wolin Huang
- 申请人地址： US CA So. San Francisco
- 专利权人： Portola Pharmaceuticals, Inc.
- 当前专利权人： Portola Pharmaceuticals, Inc.
- 当前专利权人地址： US CA So. San Francisco
- 主分类号： A61K38/45
- IPC分类号： A61K38/45 ; A61K38/48 ; A61P9/00 ; A61K31/517 ; C07D409/12 ; A61P7/00 ; A61K38/46 ; A61K31/60
摘要：
The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
信息查询
IPC分类:
